Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based Relative Induction Score Approach
Authors:
Open Access
- 1 February 2017
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 45 (2) , 198-207
Abstract
Metabolism enzyme induction-mediated drug-drug interactions need to be carefully characterized in vitro for drug candidates to predict in vivo safety risk and therapeutic efficiency. Currently, both the Food and Drug Administration and European Medicines Agency recommend using primary human hepatocytes as the gold standard in vitro test system for studying the induction potential of candidate drugs on cytochrome P450 (CYP), CYP3A4, CYP1A2, and CYP2B6. However, primary human hepatocytes are known to bear inherent limitations such as limited supply and large lot-to-lot variations, which result in an experimental burden to qualify new lots. To overcome these shortcomings, a renewable source of human hepatocytes (i.e., Corning HepatoCells) was developed from primary human hepatocytes and was evaluated for in vitro CYP3A4 induction using methods well established by the pharmaceutical industry. HepatoCells have shown mature hepatocyte-like morphology and demonstrated primary hepatocyte-like response to prototypical inducers of all three CYP enzymes with excellent consistency. Importantly, HepatoCells retain a phenobarbital-responsive nuclear translocation of human constitutive androstane receptor from the cytoplasm, characteristic to primary hepatocytes. To validate HepatoCells as a useful tool to predict potential clinical relevant CYP3A4 induction, we tested three different lots of HepatoCells with a group of clinical strong, moderate/weak CYP3A4 inducers, and noninducers. A relative induction score calibration curve-based approach was used for prediction. HepatoCells showed accurate prediction comparable to primary human hepatocytes. Together, these results demonstrate that Corning HepatoCells is a reliable in vitro model for drug-drug interaction studies during the early phase of drug testing.Keywords
This publication has 36 references indexed in Scilit:
- Hepatic Drug-Metabolizing Enzyme Induction and Implications for Preclinical and Clinical Risk AssessmentToxicologic Pathology, 2010
- Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolamBritish Journal of Clinical Pharmacology, 2010
- Nuclear Translocation of Adenoviral-Enhanced Yellow Fluorescent Protein-Tagged-Human Constitutive Androstane Receptor (hCAR): A Novel Tool for Screening hCAR Activators in Human Primary HepatocytesDrug Metabolism and Disposition, 2009
- Current Industrial Practices in Assessing CYP450 Enzyme Induction: Preclinical and ClinicalThe AAPS Journal, 2008
- HepaRG Cells as an in Vitro Model for Evaluation of Cytochrome P450 Induction in HumansDrug Metabolism and Disposition, 2008
- Relative Activation of Human Pregnane X Receptor versus Constitutive Androstane Receptor Defines Distinct Classes of CYP2B6 and CYP3A4 InducersThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Use of Immortalized Human Hepatocytes to Predict the Magnitude of Clinical Drug-Drug Interactions Caused by CYP3A4 InductionDrug Metabolism and Disposition, 2006
- Experimental and Clinical Evidence for Loss of Effect (Tolerance) during Prolonged Treatment with Antiepileptic DrugsEpilepsia, 2006
- EXPRESSION AND INDUCTION POTENTIAL OF CYTOCHROMES P450 IN HUMAN CRYOPRESERVED HEPATOCYTESDrug Metabolism and Disposition, 2005
- Stereoselective interaction of sulfinpyrazone with racemic warfarin and its separated enantiomorphs in man.Circulation, 1982